SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (1895)9/30/1997 3:12:00 AM
From: Henry Niman   of 6136
 
John, Your response to my earlier post on thestreet.com piqued my interest. When I read the article in thestreet.com, I thought that the viral load at the time of the switch was a bit high. However, I just read an AGPH report that indicated that their study successfully switched patients whose average viral load was even higher. Both studies used fairly small numbers of patients, but the frequency was quite high (possible all) in both instances, but in opposite diections (virtually all of AGPH's patients were successfully switch while virually none of the patients in the abstract describe in thestreet.com were). I think that someone on this board had posted that the patients in the latter study had failed several other drugs prior to developing resistance to Viracept.

Thus the two studies may be apples and oranges (results on patients that have had poor success previously may not be comparable to new patients that start with a given PI). I'm not that familiar with the initial patient data suggesting that Viracept was the PI of choice to start treatment. Has there been a study similar to AGPH's (patients start with another PI and are the unsuccessfully switched?). If earlier trials used patients that had previously failed several earlier treatments, then such data would be comparable to the recent abstract described in thestreet, which would call into question AGPH's claim that Viracept is the PI of choice to begin therapy.
Have the various PIs been tested under similar circumstances i.e.

1) failed prior treatment followed by introduction of PI and then switched to another PI (only variable is PI)

2) new patient started with one PI and then switched (again varying PI)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News